Key clinical point: The MammaPrint gene signature’s prognostic performance in invasive lobular carcinoma (ILC) is similar to that in invasive ductal carcinoma (IDC).
Major finding: The 5-year distant metastasis–free survival rate with a MammaPrint-classified high genomic risk was 92.1% in women with IDC vs. 88.1% in women with ILC, with overlapping 95% confidence intervals.
Study details: An exploratory subgroup analysis of 5,313 women with early-stage breast cancer (487 with ILC and 4,826 with IDC) participating in a phase 3 randomized controlled trial of risk-guided adjuvant chemotherapy (MINDACT trial).
Disclosures: The study was funded with support from the Breast Cancer Research Foundation. Dr. Metzger disclosed consulting fees from AbbVie, Genentech, Roche, and Pfizer.
Metzger O et al. EBCC-12 Virtual Conference. Abstract 6.